Interview: Adimab's Gerngross seeks two sweethearts
This article was originally published in Scrip
Executive Summary
Adimab, the firm that over the past couple of years has been quietly signing up a large section of the big pharma community to "test-drive" its yeast-based rapid antibody discovery technology, is gearing up for the next stage in its business.